ECM specialists Xylyx Bio launch skin care brand

“Our goal at VIVIQ™ is to set a new standard in premium clinical skincare. By combining our scientific expertise in advanced biomaterials with a signature brand aesthetic, VIVIQ is empowering educated consumers to address their specific skin needs,’ ​says VIVIQ Co-Founder Andrea Nye, in today’s media release about the new brand.

And while Nye also serves as CEO of Xylyx, she has a somewhat conventional founder story in that a personal skin care need and her own lived experience with VIVIQ’s unique ingredient technology precipitated the brand launch: “Our skin is under constant assault from photodamage, oxidation, injury, and the normal progression of aging. I realized this personally after a serious accident left me with severe scarring on my face. Despite hundreds of products on the market and a lot of hype, I couldn't find any truly effective solutions. With a pressing need and a deep understanding of the science, we knew we could do better.”​

There’s a patented peptide blend behind the VIVIQ Skin Health launch

The extracellular matrix (ECM) produces short peptides; and it’s a proprietary blend of these matrikines—patented as Matrikynes—that are central to the VIVIQ Advanced Dermal Repair Cream formula.

Dr John O'Neill, who’s Co-Founder of both VIVIQ Skin Health and Xylyx Bio, explains, “VIVIQ's Matrikynes biotechnology contains a proprietary combination of powerful regenerative multi-peptide molecules that help instruct our skin to rebuild and restore a healthy appearance.”​

“By supporting the structural building blocks of skin,” ​he says, “Matrikynes bioactives reduce the appearance of redness, wrinkles, and fine lines to promote radiant, resilient, smoother-looking skin.”​

Biotech experts bridge skin care and medical science

Besides the leadership overlap, Xylyx Bio and VIVIQ appear to be separate and distinct ventures. But Xylyx Bio research and technology is clearly relevant to the brand.

Xylyx Bio serves the medical industry with a supply of extracellular matrix (ECM) substrates of some 8 human tissues, including skin, as well as with testing capabilities that explore disease biology and the efficacy of various compounds.

The desired outcome of Xylyx Bio’s products and services is new drug discovery. And as the company’s about page explains, “with deep scientific expertise and understanding of the relationship between the cellular microenvironment and complex diseases, our team of scientists and engineers is championing the paradigm shift toward more biologically relevant platforms, with the ultimate goal of creating and delivering effective science-based solutions.”​